StockData
SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31

Sionna Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.01+0.12 (+3.08%)

Close on Oct 19, 2026

Market cap
$181.05M
P/E (TTM)
–
Dividend yield
–

SEC filings

22 of Sionna Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 9, 2026Sep 14, 2026SEC EDGAR
Current report8-KAug 10, 2026Aug 10, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 6, 2026SEC EDGAR
Current report8-KAug 6, 2026Aug 6, 2026SEC EDGAR
Current report8-KJun 17, 2026Jun 18, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 12, 2026SEC EDGAR
Current report8-KMay 12, 2026May 12, 2026SEC EDGAR
Proxy statementDEF 14AJun 17, 2026Apr 27, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 2, 2026SEC EDGAR
Current report8-KMar 2, 2026Mar 2, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 5, 2025SEC EDGAR
Current report8-KNov 5, 2025Nov 5, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 11, 2025SEC EDGAR
Current report8-KAug 11, 2025Aug 11, 2025SEC EDGAR
Current report8-KJun 12, 2025Jun 13, 2025SEC EDGAR
Current report8-KJun 4, 2025Jun 4, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 12, 2025SEC EDGAR
Current report8-KMay 12, 2025May 12, 2025SEC EDGAR
Proxy statementDEF 14AJun 12, 2025Apr 29, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 20, 2025SEC EDGAR
Current report8-KMar 20, 2025Mar 20, 2025SEC EDGAR
Current report8-KFeb 6, 2025Feb 10, 2025SEC EDGAR